The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer

被引：19

作者：

Cheng, Yue ^{[1
]}

Wang, Meiqi ^{[1
]}

Zhou, Junliang ^{[1
]}

Dong, Huanhuan ^{[1
]}

Wang, Shuqing ^{[1
]}

Xu, Hui ^{[1
]}

机构：

[1] Harbin Med Univ, Canc Hosp, Dept Clin Lab, 150 Haping Rd, Harbin 150081, Peoples R China

来源：

GENES | 2021年 / 12卷 / 03期

基金：

中国国家自然科学基金;

关键词：

N6-methyladenosine (m(6)A); methyltransferases; demethylases; m(6)A-binding proteins; NSCLC; EPITHELIAL-MESENCHYMAL TRANSITION; MYC MESSENGER-RNA; NUCLEAR-RNA; YTH DOMAIN; M(6)A; PROLIFERATION; METHYLATION; TRANSLATION; PROTEINS; BINDING;

D O I：

10.3390/genes12030440

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

N6-methyladenosine (m(6)A) is one of the most prevalent epigenetic modifications of eukaryotic RNA. The m(6)A modification is a dynamic and reversible process, regulated by three kinds of regulator, including m(6)A methyltransferases, demethylases and m(6)A-binding proteins, and this modification plays a vital role in many diseases, especially in cancers. Accumulated evidence has proven that this modification has a significant effect on cellular biological functions and cancer progression; however, little is known about the effects of the m(6)A modification in non-small cell lung cancer (NSCLC). In this review, we summarized how various m(6)A regulators modulate m(6)A RNA metabolism and demonstrated the effect of m(6)A modification on the progression and cellular biological functions of NSCLC. We also discussed how m(6)A modification affects the treatment, drug resistance, diagnosis and prognosis of NSCLC patients.

引用

页数：15

共 127 条

[1] N6-methyladenosine marks primary microRNAs for processing [J].

Alarcon, Claudio R. ;

Lee, Hyeseung ;

Goodarzi, Hani ;

Halberg, Nils ;

Tavazoie, Sohail F. .

NATURE, 2015, 519 (7544) :482-+

[2] Update 2020: Management of Non-Small Cell Lung Cancer [J].

Alexander, Mariam ;

Kim, So Yeon ;

Cheng, Haiying .

LUNG, 2020, 198 (06) :897-907

[3] THE C-PROTEINS OF HELA 40S NUCLEAR RIBONUCLEOPROTEIN-PARTICLES EXIST AS ANISOTROPIC TETRAMERS OF (C1)3 C2 [J].

BARNETT, SF ;

FRIEDMAN, DL ;

LESTOURGEON, WM .

MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (02) :492-498

[4] THE CORE PROTEIN-A2 AND PROTEIN-B1 EXIST AS (A2)3B1 TETRAMERS IN 40S NUCLEAR RIBONUCLEOPROTEIN-PARTICLES [J].

BARNETT, SF ;

THEIRY, TA ;

LESTOURGEON, WM .

MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (02) :864-871

[5] Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? [J].

Bell, Jessica L. ;

Waechter, Kristin ;

Muehleck, Britta ;

Pazaitis, Nikolaos ;

Koehn, Marcel ;

Lederer, Marcell ;

Huettelmaier, Stefan .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (15) :2657-2675

[6] IDENTIFICATION AND CHARACTERIZATION OF PACKAGING PROTEINS OF CORE 40S HNRNP PARTICLES [J].

BEYER, AL ;

CHRISTENSEN, ME ;

WALKER, BW ;

LESTOURGEON, WM .

CELL, 1977, 11 (01) :127-138

[7]

Bokar JA, 1997, RNA, V3, P1233

[8] The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications [J].

Burger, AM ;

Seth, AK .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2217-2229

[9] Regulation of cancer cell metabolism [J].

Cairns, Rob A. ;

Harris, Isaac S. ;

Mak, Tak W. .

NATURE REVIEWS CANCER, 2011, 11 (02) :85-95

[10] The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 [J].

Cao, R ;

Zhang, Y .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2004, 14 (02) :155-164

← 1 2 3 4 5 6 7 8 9 10 →